-
The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.
Nov 1, 2021
-
230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development
Nov 4, 2021
-
The new global Rare Disease center of Emmes expects accelerating growth from US and European biotechs
Nov 2, 2021
-
Biofortuna has more than doubled its manufacturing capacity following its relocation to new state-of-the-art facilities in Deeside, North Wales.
Nov 2, 2021
-
Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base
Nov 4, 2021
-
Doloromics has announced the appointment of Dr. Chris Flores as their new President and Chief Research and Development Officer.
Nov 7, 2021
-
St. Joseph’s Health and Renalytix Partner to Advance Value-Based Kidney Health in New York. Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease.
Nov 8, 2021
-
Aug 28, 2021
-
Renalytix Plc today announced the publication of results from an external chronic kidney disease budget impact analysis projecting 5-year savings of $1.1 billion for a population of 100,000 patients with type 2 diabetes (T2DKD) and chronic kidney disease tested with the Renalytix KidneyIntelX™ testing solution. Savings were driven by more effective pharmacy management and appropriate specialist referral compared to current standard of care for patients at high risk for disease progression and kidney failure.
Aug 25, 2021
-
Certara’s Simcyp COVID-19 Vaccine Model uses biosimulation to improve decision-making and help optimize dosing regimens of COVID-19 vaccines. Certara calibrated its model using the structure of actual COVID-19 vaccines and validated it by replicating the published clinical data. The model, which is incorporated in Certara’s Vaccine Simulator™, addresses important questions such as differences in response with age and ethnicity, optimal timing between doses and expected duration of antibody response.
Aug 25, 2021
-
Aug 25, 2021
-
Viedoc Technologies has been presented with its ISO/IEC 27001:2013 certificate affirming that the company’s global operation adheres to the internationally recognized standard for information security management
Aug 23, 2021
-
Fusion Antibodies plc (AIM: FAB) announces that is has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE (EUFI.PA) group company; a leading provider of products and services to the drug discovery industry.
Aug 23, 2021
-
Ready-to-use, liquid stable Clinical Reference Materials for Microprotein testing procedures for urine and CSF samples are now available from VERICHEM LABORATORIES.
Aug 1, 2021
-
Jul 31, 2021
-
Glyscend Inc has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy.
Aug 2, 2021
-
NanoImaging Services today announced the hire of its first Chief Operating Officer, Brian Conkle, as the company continues its rapid growth.
Aug 4, 2021
-
Many cancer clinical research trials were put on hold during Covid – now Panthera Biopartners and Rutherford Health are working in partnership to accelerate oncology research in order to provide improved care for patients.
Aug 11, 2021
-
CytoSMART introduces new, label-free live-cell microscopy solutions with high image quality
Aug 9, 2021
-
Biotium Launches Optimized Solution for Exosome Detection by Flow Cytometry
Aug 11, 2021